Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
GSK Investigational Site, Iasi, Romania
General Practice Research Database, London, United Kingdom
The University of Chicago, Chicago, Illinois, United States
1268.17.02003 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
1268.17.01034 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
1268.17.01027 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States
Pfizer Investigational Site, Omaha, Nebraska, United States
GSK Investigational Site, Simferopol, Ukraine
Asthma and Allergy Research Group, University of Dundee, Dundee, Tayside, United Kingdom
352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary
352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Novartis Investigative Site, Ottawa, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.